JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2015, 64(5):173-177 | DOI: 10.36290/csf.2015.036

Drugs and health care expenditure on the aging population

Petra Marešová1, Hana Mohelská1, Kamil Kuča2,3,*
1 University of Hradec Králové, Faculty of Informatics and Management
2 University of Hradec Králové, Center for Basic and Applied Research, Hradec Králové, Czech Republic
3 University Hospital Hradec Králové, Biomedical Research Center, Hradec Králové, Czech Republic

The aim of this article is to identify the main factors that affect future trends in healthcare expenditures from the perspective of the anticipated ageing of the population. Attention shall be focused on the elderly demography, the inhabitants' pensions and their expenditures on drugs. The article also shows the results of acase study concerning the use of particular types of drugs by elderly people in the Czech Republic and in European union.
For the purpose of this article, Iemployed aliterature search method that uses available sources describing the determinants of public healthcare expenditure and the use of selected types of drugs by the ageing population. The current situation in EU Member Countries is addressed through an analysis of public expenditure using data from public databases, such as Eurostat or OECD. The types of drugs designed for the ageing population are focused on the Czech Republic.
It follows from the executed analysis that the basic determinants of public healthcare expenditure are the demographic structure, income, the legislative conditions and productivity. The aim of effective public health care spending should not only be to achieve ahigher age, but also to enable the inhabitants to prolong the period of their work productivity and self-sufficiency. Aging population defines market opportunities open to companies from various sectors.

Keywords: aging; population; aging population; costs; health care; expenditure on drugs; strategic plan

Received: July 26, 2015; Accepted: October 5, 2015; Published: May 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Marešová P, Mohelská H, Kuča K. Drugs and health care expenditure on the aging population. Čes. slov. farm. 2015;64(5):173-177. doi: 10.36290/csf.2015.036.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Žumárová M. Subjektivní pohoda a kvalita života seniorů. 1. vydání. Prešov: Akcent print 2012.
    2. Laurance J. Why an ageing population is the greatest threat to society, The Independent. 2002. Available from: http://www.independent.co.uk/news/uk/home-news/why-an-ageing-population-is-the-greatest-threat-to-society-656997.html
    3. WHO: Dementia. The Website of WHO 2014. http://www.who.int/mediacentre/factsheets/fs362/en/
    4. European Commission. The impact of ageing on public expenditure: projections for the EU25 Member States on pensions, health care, longterm care, education and unemployment transfers. The report of the Economic Policy Committee and the Directorate General 2006.
    5. Bloom D. E., Boersch-Supan A., McGee P., Seike A. Population Aging: Facts, Challenges, and Responses. 2011. PGDA Working Paper No. 71.
    6. Vellas B., Hausner L., Frolich L., Cantet C., et al. Progression of Alzheimer disease in Europe: Data from the European ICTUS study. Current Alzheimer Research. 2012; 9(8), 902-912. Go to original source... Go to PubMed...
    7. Allegri R. F., Butman J., Arizaga R. L., et al. Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina. Int Psychogeriatr. 2007; 19, 705-718. Go to original source... Go to PubMed...
    8. Wang G., Cheng Q., Zhang S., et al. Economic impact of dementia in developing countries: an evaluation of Alzheimer-type dementia in Shanghai, China. J Alzheimer Dis. 2008; 15, 109-115. Go to original source... Go to PubMed...
    9. Herrmann N., Lanctôt K. L., Sambrook R., et al. The contribution of neuropsychiatric symptoms to the cost of dementia care. Int J Geriatr Psychiatry. 2006; 21, 972-976. Go to original source... Go to PubMed...
    10. Marshall M., Tibbs M. A. Social work and people with dementia. Bristol 2006. The Policy Press 248. Go to original source...
    11. Wimo A., Gustavsson A., McDaid D., Ersek K., Georges J., Gulacsi L, et al. The economic impact of dementia in Europe in 2008: cost estimates from the Eurocode project. Int J Geriatr Psychiatry 2010; 26, 825-832. Go to original source... Go to PubMed...
    12. Marešová P., Klímová B., Kuča K. Alzheimerova nemoc: význam nových léků a národní strategie pro snížení nákladů na léčbu. Čes. slov. Farm. 2015; 64, 25-30. Go to original source...
    13. Geogonline. Opportunities from an Ageing Population. Website of the Geogonline.uk. 2013. Available from: www.geogonline.org.uk/Opportunities
    14. OECD: Public spending on healthand long-term care: a new setof projection. 2013. Available from: http://www.oecd.org/eco/growth/Health%20FINAL.pdf
    15. Eurostat. European database. 2015. Available from: http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=ilc_di04〈=en
    16. Pettinger T. The Impact of an Ageing Population on the Economy, Economics Help Revision. 2013. Available from: http://www.economicshelp.org/blog/8950/society/impact-ageing-population-economy/
    17. Mohelská H., Marešová P., Kuča K. Economics aspects of ageing population. In: WCBEM: 3rd World Conference on Business, Economics and Management (BEM-2014) Rome-ITALY on 09 -11 April 2014. Roma 2014; 6.
    18. Gola P. Familyhealth care costsgrow. 2013. http://www.investujeme.cz/rodinne-vydaje-za-zdravotni-peci-porostou/#ixzz3dtC6j6m2
    19. Práznovcová L. Farmakoterapie seniorů v České republice: v kontextu k farmakoekonomice. Česká geriatrická revue 2003; 4.
    20. Institut důstojného stárnutí. Farmakoterapie v domovech pro seniory, ústavech sociální péče a ústavech dlouhodobé péče 2015. http://www.dustojnestarnuti.cz/zdravi/farmakoterapie-v-domovechpro-seniory-ustavech-socialni-pece-a-ustavech-dlouhodobe-pece/
    21. Schmader T., et al. Stereotype threat deconstructed. Current Directions in Psychological Science 2010; 19(1), 14-18. Go to original source...
    22. Castleden C. M., et al. Increased sensitivity to nitrazepam in old age: BMJ 1977; I, 10-12.
    23. Grundmann M. Problémy s podáváním léků ve stáří: nežádoucí účinky léků. Interní medicína pro praxi 2001; 2, 82-84.

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.